Lead Sponsor

Medstar Health Research Institute

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Have a solid tumor malignancy that is metastatic or locally advanced/unresectable
•Progression through standard therapy
•Histological documentation of cancer
•Must be off prior chemotherapy or radiation therapy for at least 3 weeks
•Must have adequate organ and marrow function prior to the start of study treatment as defined by the protocol
•Must be able to swallow oral medication (dasatinib must be swallowed whole)
•Must be available for protocol-required follow-up

•Patients with a malignancy (other than the one treated in this study) which required radiotherapy or systemic therapy within the past 5 years
•Symptomatic brain metastasis that is either untreated or uncontrolled by surgery and or radiotherapy
•A known, prior, severe (NCI CTC Grade 3/Grade 4) history of hypersensitivity reaction to a drug formulated in Cremophor (polyoxyethylated castor oil)
•A serious, uncontrolled medical disorder or active infection including pericardial or pleural effusion of any grade,uncontrolled or significant cardiovascular disease,a bleeding disorder.

Related studies

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT07060989 · Advanced Solid Tumors

NCT05533697 · Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

Solid Tumors Using Ixabepilone and Dasatinib